China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released
/PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted...
Mabwell Taizhou Prnewswire Mabwell Significant New Drugs Development National Key Rd Programmes Urothelial Carcinoma Objective Response Rate
Source: prnewswire.com